論文・技術情報追加のお知らせ

1. Levofloxacin-associated tendon disorders: Sex-, age-, and route-specific disproportionality analysis using FAERS and JADER.

レボフロキサシン関連腱障害の性・年齢・投与経路別不均衡分析。

対象DB：FAERS,JADER

2. Vorasidenib-Induced Acute Liver Injury.

ヴォラシデニブ投与に伴う急性重症肝障害の症例とFAERS解析。

対象DB：FAERS

3. Drugs associated with retroperitoneal fibrosis: assessment of the 1969-2025 Food and Drug Administration (FDA) pharmacovigilance database.

FAERSデータに基づく後腹膜線維症誘発薬剤の不均衡分析調査。

対象DB：FAERS

4. Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian Randomization.

GLP-1受容体作動薬と糖尿病足合併症リスクに関する統合解析。

対象DB：FAERS

5. Adverse events associated with immune checkpoint inhibitors in combination with chemotherapy in lung cancer: a real-world analysis.

肺がん治療におけるICI・抗がん剤併用療法の副作用シグナル解析。

対象DB：FAERS

6. Real-world safety profile of alectinib: a 10-year pharmacovigilance study based on the FDA adverse event reporting system.

ALK陽性非小細胞肺がん治療薬アレクチニブの10年間市販後調査。

対象DB：FAERS

7. Trastuzumab-TKI combination in HER2-Positive tumors: a FAERS-Based safety profile and multimodal analysis of Tanespimycin's role in enhancing targeting of the HSP90AA1-PI3K-Akt-mTOR axis.

HER2陽性腫瘍におけるトラスツズマブ・TKI併用の安全性評価。

対象DB：FAERS

8. Elucidating adverse drug reactions and underlying molecular mechanisms of ivermectin through pharmacovigilance and multi-omics analysis.

イベルメクチン関連有害事象のFAERS解析と分子メカニズム解明。

対象DB：FAERS

9. Peripheral blood cells and immune checkpoint inhibitor-associated myocarditis: a retrospective clinical study with pharmacovigilance and single-cell analysis.

免疫チェックポイント阻害薬関連心筋炎における末梢血細胞の解析。

対象DB：FAERS

10. Kidney injury associated with direct oral anticoagulants: a comparative study of direct thrombin inhibitors and factor Xa inhibitors based on literature and database analysis.

直接経口抗凝固薬（DOAC）間における腎障害リスクの比較調査。

対象DB：FAERS

11. Drug-associated osteoarthritis signals in FAERS: A pharmacovigilance study.

FAERSにおける薬剤関連変形性関節症シグナルの不均衡分析。

対象DB：FAERS

12. US Food and Drug Administration's Adverse Event Reporting System-Highly Limited for Causal Inference in Dermatology.

米国FDA自発報告データベースの限界に関する考察コメント。

対象DB：FAERS

13. Detection of Signals for Smell and Taste Disorders Associated with Z-drugs: A Disproportionality Analysis of the FAERS Database.

Z薬（睡眠薬）投与に伴う嗅覚・味覚障害シグナルの不均衡分析。

対象DB：FAERS

14. Antipsychotic-associated obsessive-compulsive symptoms and disorder: scoping review of mechanisms, comparative epidemiology and clinical implications.

抗精神病薬誘発性強迫症状・強迫症に関するスコープレビュー。

対象DB：FAERS,VigiBase

15. Safety evaluation of zuranolone in the management of postpartum depression: A real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS).

産後うつ病治療薬ズラノロンの市販後安全性プロファイル評価。

対象DB：FAERS

16. Pharmacovigilance analysis of immune checkpoint inhibitor-associated optic nerve toxicity based on the FAERS database.

免疫チェックポイント阻害薬関連視神経毒性の不均衡分析調査。

対象DB：FAERS

17. Anti-HER2 therapy-associated echocardiography-related cardiac dysfunction and severe outcomes: Comparison of disproportionality and report-level cluster analyses.

抗HER2療法に伴う心機能障害の心エコー指標と重症度の解析。

対象DB：FAERS

18. Endothelial and Vascular Toxicity Signals Associated With Doxorubicin: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.

ドキソルビシン関連血管毒性シグナルのFAERS不均衡分析調査。

対象DB：FAERS

19. Novel inhibitors of BCRP found among drugs used in the treatment of cancer.

抗がん剤におけるBCRPトランスポーター阻害作用の新規同定。

対象DB：FAERS

20. QT Prolongation, Ventricular Arrhythmia, and Cardiac Arrest Signals During Ceftriaxone Co-therapy with Individual Proton Pump Inhibitors: A Multidatabase Study.

セフトリアキソンとPPI併用時における心電図異常シグナル解析。

対象DB：CVAR,FAERS

21. Integrating pharmacovigilance and machine learning: bleeding signal detection and risk prediction for oral anticoagulants in cancer patients.

経口抗凝固薬投与がん患者における出血シグナルと機械学習予測。

対象DB：FAERS

22. Interstitial pneumonia signals of apalutamide, darolutamide, and enzalutamide in FAERS and JADER.

前立腺がん治療薬（ARS阻害薬3種）の間質性肺炎シグナル比較。

対象DB：FAERS,JADER

23. Integration of Mendelian Randomization and FDA Adverse Event Reporting System Database Analysis Reveals the Association Between Ergotamine and Aortic and Mitral Valve Diseases.

メンデル無作為化とFAERSを統合した心臓弁膜症関連薬剤の特定。

対象DB：FAERS

24. Multi-database pharmacovigilance identifies disproportionate reporting of hepatobiliary events with avacopan: an integrative study with network pharmacology and interpretable machine learning.

アバコパン関連の重篤な肝胆道障害における多国籍DB安全性解析。

対象DB：EudraVigilance,JADER

25. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fournier Gangrene: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database.

SGLT2阻害薬とフルニエ壊疽の関連性に関する不均衡分析。

対象DB：JADER

26. Body Mass Index-Related Trends in Adverse Events with Enfortumab Vedotin: Analysis of a Pharmacovigilance Database and Medical Records.

エンホルツマブ ベドチン関連有害事象とBMIの関連性解析。

対象DB：JADER

27. Age-Related Time-to-Onset Analysis of Drug-Associated Erythema Multiforme Using the Japanese Adverse Drug Event Report Database.

薬剤性多形紅斑の発現時期と年齢層による影響の不均衡分析。

対象DB：JADER

28. Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database.

リラグルチド等における自殺・自傷関連事象の自発報告パターン。

対象DB：EudraVigilance

29. Delayed Neurologic and Enterocolitis Reporting Patterns for Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in EudraVigilance.

シルタカブタゲン オートルーセル投与後の遅発性神経毒性解析。

対象DB：EudraVigilance

30. Tuberculosis during JAK inhibitor or TNF-alpha inhibitors therapy: a disproportionality analysis from WHO pharmacovigilance database.

JAK阻害薬およびTNF阻害薬使用患者における結核発症リスク。

対象DB：VigiBase

31. A Systematic Review and a VigiBase Study of Accidental Clozapine Intoxications in Children and Adolescents.

小児におけるクロザピン誤飲事故のシグナル検出と文献レビュー。

対象DB：VigiBase

32. Mental health safety profile of CFTR modulators in pediatrics and adults: insights from the French pharmacovigilance database and from VigiBase.

嚢胞性繊維症治療薬（CFTR調節薬）の精神的安全性解析。

対象DB：FPVD,VigiBase

33. Drug-associated central nervous system vasculitis and reversible cerebral vasoconstriction syndrome: A global disproportionality analysis of the WHO pharmacovigilance database (VigiBase).

薬剤性中枢神経系血管炎およびRCVSのFAERS不均衡分析。

対象DB：VigiBase

34. Continuous multidimensional physiological monitoring redefines early warning and preemptive treatment for neutropenic sepsis following cisplatin chemotherapy in non-small cell lung cancer.

シスプラチン投与中の生体モニタリングによる急性腎障害予測。

対象DB：JADER

35. Survival in Extracorporeal Cardiopulmonary Resuscitation for Pediatric In-Hospital Cardiac Arrest: Nationwide Cohort Study in Japan, 2011-2022.

小児院内心停止に対する体外式心肺蘇生法の生存率と転帰調査。

対象DB：DPC

36. Development and External Validation of a Machine Learning-Based Bleeding Risk Score for Patients Undergoing Percutaneous Coronary Intervention.

経皮的冠動脈形成術後の出血リスク予測機械学習モデルの開発。

対象DB：DPC

37. Real-world survey of hematopoietic stem cell transplantation in Japan using a nationwide administrative claims database.

日本における造血幹細胞移植の実態に関する全国データベース解析。

対象DB：DPC

38. Evolution of Real-World Treatment Patterns over Time in Patients with HER2-Negative Advanced Gastric Cancer: A Retrospective Database Cohort Study from Japan.

HER2陰性進行・再発乳がんにおけるリアルワールド治療推移。

対象DB：MDV

39. Robot-assisted colectomy is associated with improved perioperative outcomes and favorable survival in stage I-III colon cancer: a nationwide overlap-weighted analysis.

結腸がんに対するロボット支援下結腸切除術の術後転帰評価。

対象DB：MDV

40. Real-World Longitudinal Treatment Outcomes for Patients with Metastatic Castration-Sensitive Prostate Cancer in Japan.

転移性去勢感受性前立腺がんにおける一次療法のリアルワールド転帰。

対象DB：MDV

41. Real-World Testing Landscape and Costs of Companion Diagnostics and Comprehensive Genomic Profiling Across Nine Solid Tumors in Japan: A 10-Year Analysis.

癌コンパニオン診断およびCGP検査の利用実態と医療費解析。

対象DB：MDV

42. Erectile dysfunction and the risk of glaucoma in men: a prospective nested case-control study using large-scale UK primary care data.

勃起不全と緑内障発症リスクの関連性に関する前向きコホート。

対象DB：CPRD

43. Epidemiology, temporal trends, and fibrosis risk stratification in metabolic dysfunction-associated steatotic liver disease in UK primary care: a population-based cohort and nested case-control study.

代謝異常関連脂肪肝炎（MASH）の疫学動向と線維化リスク層別化。

対象DB：CPRD

44. Nephrology review frequency, associated factors, and outcomes among people with chronic kidney disease G5: a population-based cohort study in England.

慢性腎臓病患者における腎臓内科受診頻度と透析導入転帰の解析。

対象DB：CPRD

45. Herpes zoster incidence rates in adults aged 18 years or older with immunocompromising or chronic conditions in England: a large retrospective cohort study (Clinical Practice Research Datalink, 2012-2019).

免疫不全成人患者における帯状疱疹発症率に関する大規模調査。

対象DB：CPRD

46. Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence.

フェノフィブラート使用と糖尿病網膜症進展抑制の関連性評価。

対象DB：CPRD

47. An investigation of the association between Juvenile rheumatic disease and growth: a retrospective matched cohort study.

若年性リウマチ性疾患と小児の成長障害リスクに関する調査。

対象DB：CPRD

48. Joint association of sedentary behaviour and physical activity with cardiovascular disease: a systematic review and meta-analysis.

座位行動と身体活動の組み合わせが心血管リスクに与える影響。

対象DB：DeSC